title: [Complementary therapies in cystic fibrosis: evidence of therapeutic benefits and treatment recommendations].
abstract: Cystic fibrosis (CF) is an autosomal-recessive disorder that predominantly affects the respiratory system. When this disease was described in 1938 the mortality rate was approximately 70 % in the first year of life. Survival has dramatically increased from a median of approximately 4 years in the 1960s to 19 years in the 1970s and 33 years in 2001 according to figures from the American Cystic Fibrosis Foundation. This impressive increase in the life expectancy of individuals with CF is undoubtedly related to recent advances in the organization of specialized CF units and to the use of new therapies against respiratory involvement.The traditional basis of treatment for CF lung disease includes nutritional support, antibiotic therapy, chest physical therapy and aerobic exercise. Preventive measures such as influenza vaccination and avoidance of tobacco smoke are also useful. Several new approaches such as ion transport therapy, protein therapy and gene therapy are currently being developed. Many studies have provided clear evidence of the therapeutic benefits of antibiotics, respiratory physiotherapy, exercise, and nutrition. In this article we review the scientific evidence on the advantages of the use of several therapeutic interventions against inflammation, increased sputum viscoelasticity and adhesiveness, and bronchial obstruction in CF patients.
authors.affiliation: Unidad de Fibrosis Quística. Hospital Infantil Universitario del Niño Jesús-Hospital de la Princesa. Madrid. España. asalacedo@hnjs.insalud.es
authors.forename: A
authors.initials: A
authors.lastname: Salcedo Posadas
authors.forename: R
authors.initials: R
authors.lastname: Girón Moreno
authors.forename: B
authors.initials: B
authors.lastname: Beltrán Bengoechea
mesh_terms: D017963:Azithromycin / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002648:Child; D000529:Complementary Therapies; D003550:Cystic Fibrosis / Q000188:drug therapy*; D003851:Deoxyribonucleases / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D017410:Practice Guidelines as Topic
chemical_list: D001993:Bronchodilator Agents; D005938:Glucocorticoids; D017963:Azithromycin; D003851:Deoxyribonucleases; D007052:Ibuprofen